丁苯酞软胶囊联合依达拉奉治疗急性脑梗死的临床效果分析  

Clinical effect analysis of butylphthalide soft capsules combined with edaravone in the treatment of acute cerebral infarction

作　　者：周展 姚丽萍 谢晓姣 ZHOU Zhan;YAO Li-ping;XIE Xiao-jiao(Pharmacy Department,Laiyang Central Hospital,Yantai 265200,China)

机构地区：[1]烟台市莱阳中心医院药剂科,265200

出　　处：《中国实用医药》2024年第9期22-25,共4页China Practical Medicine

摘　　要：目的分析急性脑梗死患者采取丁苯酞软胶囊联合依达拉奉治疗的临床效果。方法50例急性脑梗死患者,以随机数字表法分为观察组和对照组,每组25例。对照组应用常规治疗+丁苯酞软胶囊治疗,观察组在对照组基础上联合依达拉奉治疗。比较两组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、改良巴氏指数(Barthel指数)、血液流变学指标[血浆粘度(PSV)、红细胞压积(HCT)、全血低切粘度(LSV)、全血高切粘度(HSV)]及临床疗效、不良反应发生率。结果观察组治疗总有效率92.0%高于对照组的68.0%,比较有统计学意义(P<0.05)。治疗后,观察组NIHSS评分(13.71±2.84)分明显更低于对照组的(16.52±3.46)分,Barthel指数(88.23±4.85)分更高于对照组的(78.61±5.34)分,比较有统计学意义(P<0.05)。治疗后,观察组PSV、HCT、LSV、HSV分别为(1.25±0.11)mPa·s、(39.26±3.22)%、(10.12±1.11)mPa·s、(5.13±2.41)mPa·s,更低于对照组的(2.62±0.24)mPa·s、(45.62±3.66)%、(12.51±0.24)mPa·s、(6.95±0.27)mPa·s,比较有统计学意义(P<0.05)。两组不良反应发生率对比无统计学意义(P>0.05)。结论在急性脑梗死治疗中应用丁苯酞软胶囊联合依达拉奉可改善神经功能与生活质量、血液流变学,提高临床疗效,且不会增加药物治疗不良反应,值得临床推广应用。Objective To analyze the clinical effect of butylphthalide soft capsules combined with edaravone in the treatment of acute cerebral infarction.Methods 50 patients with acute cerebral infarction were divided into an observation group and a control group by random number table,with 25 cases in each group.The control group was treated with conventional treatment plus butylphthalide soft capsules,and the observation group was treated with edaravone on the basis of the control group.Both groups were compared in terms of National Institutes of Health Stroke Scale(NIHSS)score,modified Barthel index,hemorheology indexes[plasma viscosity(PSV),hematocrit(HCT),low shear viscosity(LSV),high shear viscosity(HSV)]before and after treatment,clinical efficacy and incidence of adverse reactions.Results The total effective rate of the observation group was 92.0%,which was higher than 68.0%of the control group,and there was a statistical significance in comparison(P<0.05).After treatment,the observation group had significantly lower NIHSS score of(13.71±2.84)points than(16.52±3.46)points in the control group,and higher Barthel index of(88.23±4.85)points than(78.61±5.34)points in the control group.There was a statistical significance in comparison(P<0.05).After treatment,PSV,HCT,LSV and HSV in the observation group were(1.25±0.11)mPa·s,(39.26±3.22)%,(10.12±1.11)mPa·s and(5.13±2.41)mPa·s,which were lower than(2.62±0.24)mPa·s,(45.62±3.66)%,(12.51±0.24)mPa·s and(6.95±0.27)mPa·s in the control group.There was a statistical significance in comparison(P<0.05).There was no statistical significance in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of butylphthalide soft capsules combined with edaravone in the treatment of acute cerebral infarction can improve neurological function,quality of life,hemorheology,and clinical efficacy,and does not increase the adverse reactions of drug therapy,which is worthy of clinical promotion and application.

关 键 词：丁苯酞软胶囊 依达拉奉 急性脑梗死 临床效果 

分 类 号：R743.33[医药卫生—神经病学与精神病学]